Abstract
Controversies on risk factors affecting immediate implant-based breast reconstruction (IBBR) still exist. We aimed to evaluate risk factors of reconstruction failure (RF) in immediate IBBR. We retrospectively reviewed 239 patients (241 breasts) who underwent immediate IBBR from 2011 to 2019. A nomogram was established to predict RF rate in stage I operation and logistic regression model was created for stage II operation. 14 (5.81%) and 7 (5.51%) reconstructive breasts experienced RF in stage I and II operation, respectively. Body mass index (BMI) [odds ratio (OR)=1.569, 95% confidence interval (CI): 1.087-2.263, p=0.016], implant/tissue expander (TE) volume>86.30% (OR=5.711, 95% CI: 1.067-30.583, p=0.042), adjuvant chemotherapy (ACT) (OR=30.094, 95% CI: 2.030-446.084, p=0.013) were independent risk factors for RF in stage I operation. The nomogram to predict RF rate in stage I operation revealed area under the curve (AUC) was 0.920 (95% CI: 0.844-0.995). Logistic regression demonstrated that mesh use was the independent predictor of RF in stage II operation (OR=47.326, 95% CI: 3.11-720.081, p=0.005). The nomogram exhibited satisfied predictive ability. Present findings enhanced our understanding of the risk factors contributing to RF and might lead us clinical decision to improve the outcome of immediate IBBR.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work is funded by grants from the Medical Health Science and Technology Project of Zhejiang Provincial Health Commission (2021RC045). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study is approved by Zhejiang Cancer Hospital Clinical Research Ethics Committee (IRB-2020-327).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All relevant data are within the manuscript and its Supporting Information files.
